Emergent BioSolutions Inc. (EBS) · Insider trading
What Emergent BioSolutions's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$1.26M
6 insiders, 57% under a plan
Net, 12 months
−$1.26M
bought less sold
Latest filing
2026-10-07
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| DeGolyer Donald WDirector | – | $784,419 | 6 | 2026-10-07 | 111,921 |
| Papa Joseph CDirector, President and CEO | $349,800 | – | 1 | 2025-05-13 | 342,500 |
| Glessner ColeenEVP, Quality & Ethics, and CPL | – | $306,080 | 1 | 2025-10-07 | 144,319 |
| Zoon Kathryn CDirector | – | $264,606 | 4 | 2026-05-01 | 80,998 |
| Richard RonaldDirector | – | $263,101 | 2 | 2025-12-05 | 98,417 |
| Fowler Neal FranklinDirector | – | $204,050 | 1 | 2025-03-12 | 101,100 |
| Dayal Sujata TyagiDirector | – | $201,130 | 3 | 2026-05-01 | 101,543 |
| Katkin KeithDirector | – | $177,600 | 2 | 2026-04-30 | 96,294 |
| White Marvin LDirector | – | $171,015 | 1 | 2024-11-11 | 54,092 |
| Williams Paul AnthonySVP, Products Business | – | $78,550 | 3 | 2026-10-01 | 156,098 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | DeGolyer Donald WDirector | Saleplan | 17,800 | 7.09 | $126,202 | 111,921 | Form 4 |
| 2026-10-01 | Williams Paul AnthonySVP, Products Business | Saleplan | 3,000 | 6.53 | $19,590 | 156,098 | Form 4 |
| 2026-07-01 | Williams Paul AnthonySVP, Products Business | Saleplan | 3,000 | 8.40 | $25,200 | 159,098 | Form 4 |
| 2026-05-01 | Dayal Sujata TyagiDirector | Saleplan | 12,781 | 8.36 | $106,849 | 101,543 | Form 4 |
| 2026-05-01 | Dayal Sujata TyagiDirector | Saleplan | 980 | 8.94 | $8,761 | 100,563 | Form 4 |
| 2026-05-01 | DeGolyer Donald WDirector | Saleplan | 14,527 | 8.36 | $121,446 | 130,675 | Form 4 |
| 2026-05-01 | DeGolyer Donald WDirector | Saleplan | 954 | 8.96 | $8,548 | 129,721 | Form 4 |
| 2026-05-01 | Zoon Kathryn CDirector | Saleplan | 16,145 | 8.36 | $134,972 | 80,998 | Form 4 |
| 2026-05-01 | Zoon Kathryn CDirector | Saleplan | 1,057 | 8.97 | $9,481 | 79,941 | Form 4 |
| 2026-04-30 | Katkin KeithDirector | Saleplan | 15,481 | 8.28 | $128,183 | 96,294 | Form 4 |
| 2026-04-01 | Williams Paul AnthonySVP, Products Business | Saleplan | 4,000 | 8.44 | $33,760 | 62,681 | Form 4 |
| 2025-12-05 | Richard RonaldDirector | Sale | 7,100 | 12.11 | $85,981 | 98,417 | Form 4 |
| 2025-12-05 | Richard RonaldDirector | Sale | 14,884 | 11.90 | $177,120 | 98,417 | Form 4 |
| 2025-11-10 | DeGolyer Donald WDirector | Sale | 17,801 | 10.54 | $187,623 | 119,858 | Form 4 |
| 2025-11-07 | Dayal Sujata TyagiDirector | Sale | 8,552 | 10.00 | $85,520 | 88,980 | Form 4 |
| 2025-10-07 | Glessner ColeenEVP, Quality & Ethics, and CPL | Sale | 30,608 | 10.00 | $306,080 | 144,319 | Form 4 |
| 2025-08-15 | Zoon Kathryn CDirector | Saleplan | 7,086 | 8.87 | $62,853 | 71,799 | Form 4 |
| 2025-08-12 | DeGolyer Donald WDirector | Sale | 7,844 | 8.65 | $67,851 | 137,659 | Form 4 |
| 2025-05-23 | Katkin KeithDirector | Saleplan | 7,844 | 6.30 | $49,417 | 86,431 | Form 4 |
| 2025-05-13 | Papa Joseph CDirector, President and CEO | Buy | 60,000 | 5.83 | $349,800 | 342,500 | Form 4 |
| 2025-03-12 | Zoon Kathryn CDirector | Sale | 10,000 | 5.73 | $57,300 | 44,482 | Form 4 |
| 2025-03-12 | Fowler Neal FranklinDirector | Sale | 35,000 | 5.83 | $204,050 | 101,100 | Form 4 |
| 2024-11-12 | DeGolyer Donald WDirector | Sale | 25,000 | 10.91 | $272,750 | 111,100 | Form 4 |
| 2024-11-11 | White Marvin LDirector | Sale | 14,287 | 11.97 | $171,015 | 54,092 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
39 × shares withheld for tax34 × grant or award7 × returned to the company1 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-08 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax F | −3,964 | 8.00 | 374,083 | Form 4 |
| 2026-06-08 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax F | −2,018 | 8.00 | 202,201 | Form 4 |
| 2026-06-08 | Williams Paul AnthonySVP, Products Business | Shares withheld for tax F | −694 | 8.00 | 162,098 | Form 4 |
| 2026-06-08 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −1,741 | 8.00 | 185,558 | Form 4 |
| 2026-04-30 | Fowler John D JrDirector | Grant or award A | +25,344 | – | 30,350 | Form 4 |
| 2026-04-30 | Katkin KeithDirector | Grant or award A | +25,344 | – | 111,775 | Form 4 |
| 2026-04-30 | Richard RonaldDirector | Grant or award A | +25,344 | – | 123,761 | Form 4 |
| 2026-04-30 | Harsanyi ZsoltDirector, Chairman | Grant or award A | +25,344 | – | 149,076 | Form 4 |
| 2026-04-30 | White Marvin LDirector | Grant or award A | +25,344 | – | 113,839 | Form 4 |
| 2026-04-30 | Fowler Neal FranklinDirector | Grant or award A | +25,344 | – | 160,847 | Form 4 |
| 2026-04-30 | Dayal Sujata TyagiDirector | Grant or award A | +25,344 | – | 114,324 | Form 4 |
| 2026-04-30 | DeGolyer Donald WDirector | Grant or award A | +25,344 | – | 145,202 | Form 4 |
| 2026-04-30 | Zoon Kathryn CDirector | Grant or award A | +25,344 | – | 97,143 | Form 4 |
| 2026-04-29 | Lindahl Richard SEVP, Chief Financial Officer | Grant or award A | +162,680 | – | 378,047 | Form 4 |
| 2026-04-29 | Papa Joseph CDirector, President and CEO | Grant or award A | +187,708 | – | 493,153 | Form 4 |
| 2026-04-29 | Glessner ColeenEVP, Quality & Ethics, and CPL | Grant or award A | +100,111 | – | 204,219 | Form 4 |
| 2026-04-29 | Williams Paul AnthonySVP, Products Business | Grant or award A | +100,111 | – | 162,792 | Form 4 |
| 2026-04-29 | Hartzel WilliamSVP, Bioservices | Grant or award A | +100,111 | – | 187,299 | Form 4 |
| 2026-04-29 | Perl JessicaSVP, General Counsel, Corp Sec | Grant or award A | +104,282 | – | 165,286 | Form 4 |
| 2026-04-29 | Lowry Simon CSVP, R&D, CMO | Grant or award A | +100,111 | – | 177,914 | Form 4 |
| 2026-03-05 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax F | −23,650 | 8.44 | 215,367 | Form 4 |
| 2026-03-05 | Papa Joseph CDirector, President and CEO | Shares withheld for tax F | −37,055 | 8.44 | 305,445 | Form 4 |
| 2026-03-05 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax F | −8,199 | 8.44 | 104,108 | Form 4 |
| 2026-03-05 | Williams Paul AnthonySVP, Products Business | Shares withheld for tax F | −9,397 | 8.44 | 66,681 | Form 4 |
| 2026-03-05 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −9,493 | 8.44 | 87,188 | Form 4 |
| 2026-03-05 | Perl JessicaSVP, General Counsel, Corp Sec | Shares withheld for tax F | −6,465 | 8.44 | 61,004 | Form 4 |
| 2026-03-05 | Lowry Simon CSVP, R&D, CMO | Shares withheld for tax F | −10,636 | 8.44 | 77,803 | Form 4 |
| 2026-03-03 | Fowler John D JrDirector | Grant or award A | +5,006 | 8.99 | 5,006 | Form 4 |
| 2026-03-01 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax F | −683 | 8.15 | 239,017 | Form 4 |
| 2026-03-01 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax F | −313 | 8.15 | 112,307 | Form 4 |
| 2026-03-01 | Williams Paul AnthonySVP, Products Business | Shares withheld for tax F | −116 | 8.15 | 76,078 | Form 4 |
| 2026-02-09 | Perl JessicaSVP, General Counsel, Corp Sec | Shares withheld for tax F | −918 | 11.03 | 67,469 | Form 4 |
| 2026-02-06 | Lindahl Richard SEVP, Chief Financial Officer | Returned to the company D | −46,155 | 10.92 | 245,342 | Form 4 |
| 2026-02-06 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax F | −5,642 | 10.92 | 239,700 | Form 4 |
| 2026-02-06 | Glessner ColeenEVP, Quality & Ethics, and CPL | Returned to the company D | −28,847 | 10.92 | 115,472 | Form 4 |
| 2026-02-06 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax F | −2,852 | 10.92 | 112,620 | Form 4 |
| 2026-02-06 | Williams Paul AnthonySVP, Products Business | Returned to the company D | −8,655 | 10.92 | 77,216 | Form 4 |
| 2026-02-06 | Williams Paul AnthonySVP, Products Business | Shares withheld for tax F | −1,022 | 10.92 | 76,194 | Form 4 |
| 2026-02-06 | Hartzel WilliamSVP, Bioservices | Returned to the company D | −5,771 | 10.92 | 97,311 | Form 4 |
| 2026-02-06 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −630 | 10.92 | 96,681 | Form 4 |
| 2025-12-14 | Lowry Simon CSVP, R&D, CMO | Shares withheld for tax F | −3,543 | 11.41 | 88,439 | Form 4 |
| 2025-12-05 | Richard RonaldDirector | Option exercise M | +25,748 | 5.02 | 124,165 | Form 4 |
| 2025-12-05 | Richard RonaldDirector | Shares withheld for tax F | −10,864 | 11.90 | 113,301 | Form 4 |
| 2025-11-11 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −610 | 10.88 | 103,082 | Form 4 |
| 2025-10-15 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax F | −4,995 | 9.60 | 291,497 | Form 4 |
| 2025-07-11 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −4,263 | 7.36 | 103,692 | Form 4 |
| 2025-06-08 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax F | −2,733 | 6.63 | 296,492 | Form 4 |
| 2025-06-08 | Williams Paul AnthonySVP, Products Business | Shares withheld for tax F | −464 | 6.63 | 85,871 | Form 4 |
| 2025-06-08 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax F | −1,249 | 6.63 | 174,927 | Form 4 |
| 2025-06-08 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −1,167 | 6.63 | 107,955 | Form 4 |
| 2025-04-30 | Sullivan Louis WDirector | Grant or award A | +34,403 | – | 139,098 | Form 4 |
| 2025-04-30 | DeGolyer Donald WDirector | Grant or award A | +34,403 | – | 145,503 | Form 4 |
| 2025-04-30 | Harsanyi ZsoltDirector, Chairman | Grant or award A | +34,403 | – | 123,732 | Form 4 |
| 2025-04-30 | Katkin KeithDirector | Grant or award A | +34,403 | – | 94,275 | Form 4 |
| 2025-04-30 | Dayal Sujata TyagiDirector | Grant or award A | +34,403 | – | 97,532 | Form 4 |
| 2025-04-30 | Zoon Kathryn CDirector | Grant or award A | +34,403 | – | 78,885 | Form 4 |
| 2025-04-30 | Fowler Neal FranklinDirector | Grant or award A | +34,403 | – | 135,503 | Form 4 |
| 2025-04-30 | White Marvin LDirector | Grant or award A | +34,403 | – | 88,495 | Form 4 |
| 2025-04-30 | Richard RonaldDirector | Grant or award A | +34,403 | – | 105,517 | Form 4 |
| 2025-04-07 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax F | −480 | 4.44 | 176,176 | Form 4 |
| 2025-04-07 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −561 | 4.44 | 109,122 | Form 4 |
| 2025-03-06 | Hartzel WilliamSVP, Bioservices | Grant or award A | +62,500 | – | 109,683 | Form 4/A |
| 2025-03-06 | Glessner ColeenEVP, Quality & Ethics, and CPL | Grant or award A | +62,500 | – | 176,656 | Form 4 |
| 2025-03-06 | Papa Joseph CDirector, President and CEO | Grant or award A | +282,500 | – | 282,500 | Form 4 |
| 2025-03-06 | Lowry Simon CSVP, R&D, CMO | Grant or award A | +62,500 | – | 91,982 | Form 4 |
| 2025-03-06 | Lindahl Richard SEVP, Chief Financial Officer | Grant or award A | +146,888 | – | 299,225 | Form 4 |
| 2025-03-06 | Williams Paul AnthonySVP, Products Business | Grant or award A | +62,500 | – | 86,335 | Form 4 |
| 2025-03-06 | Perl JessicaSVP, General Counsel, Corp Sec | Grant or award A | +62,500 | – | 68,387 | Form 4 |
| 2025-03-05 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −292 | 5.80 | 47,183 | Form 4 |
| 2025-03-01 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax F | −683 | 7.48 | 152,337 | Form 4 |
| 2025-03-01 | Williams Paul AnthonySVP, Products Business | Shares withheld for tax F | −116 | 7.48 | 23,835 | Form 4 |
| 2025-03-01 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax F | −313 | 7.48 | 114,156 | Form 4 |
| 2025-02-28 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax F | −1,073 | 7.48 | 153,020 | Form 4 |
| 2025-02-28 | Williams Paul AnthonySVP, Products Business | Shares withheld for tax F | −382 | 7.48 | 23,951 | Form 4 |
| 2025-02-12 | Lindahl Richard SEVP, Chief Financial Officer | Returned to the company D | −16,916 | – | 154,093 | Form 4 |
| 2025-02-12 | Glessner ColeenEVP, Quality & Ethics, and CPL | Returned to the company D | −5,913 | – | 138,547 | Form 4 |
| 2025-02-12 | Glessner ColeenEVP, Quality & Ethics, and CPL | Returned to the company D | −24,078 | – | 114,469 | Form 4 |
| 2025-02-09 | Perl JessicaSVP, General Counsel, Corp Sec | Shares withheld for tax F | −918 | 10.00 | 5,887 | Form 4 |
| 2024-12-15 | Lowry Simon CSVP, R&D, CMO | Grant or award A | +29,482 | – | 29,482 | Form 4 |
| 2024-12-08 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax F | −18,674 | 9.01 | 144,460 | Form 4 |
| 2024-11-11 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax F | −632 | 11.97 | 47,475 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.